Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?

Since the introduction of imatinib for the treatment of chronic myelogenous leukemia, several oncogenic mutations have been identified in various malignancies that can serve as targets for therapy. More recently, a deeper insight into the mechanism of antitumor immunity and tumor immunoevasion have...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyan, Zhou, Qing, Xu, Yan, Chen, Minjiang, Zhao, Jing, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689740/
https://www.ncbi.nlm.nih.gov/pubmed/29156850
http://dx.doi.org/10.18632/oncotarget.21160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689740/
https://www.ncbi.nlm.nih.gov/pubmed/29156850
http://dx.doi.org/10.18632/oncotarget.21160

Ejemplares similares